Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 684 results for kidney or kidneys or renal

  1. What is the optimal timing of administration of carbohydrate drinks as part of a preoperative fasting strategy?

    crystalloid use has become more common after reports of increased risks of acute kidney injury, coagulopathy and mortality with colloid....

    Research recommendation
    Published
    26 October 2020

  2. Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

    Technology appraisal guidance
    Published
    1 November 2023
    View recommendations

    Sections for TA928

  3. Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 July 2021
    View recommendations

    Sections for TA712

  4. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

    Technology appraisal guidance
    Published
    25 November 2009
    View recommendations

    Sections for TA184

  5. Chronic kidney disease (stage 5): peritoneal dialysis (CG125)

    This guidance has been updated and replaced by NICE guideline NG107.

    Withdrawn guideline

  6. Acute kidney injury: prevention, detection and management (CG169)

    This guidance has been updated and replaced by NICE guideline NG148.

    Withdrawn guideline

  7. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

    Medtech innovation briefing
    Published
    11 March 2016

  8. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

    Technology appraisal guidance
    Published
    27 March 2013
    View recommendations

    Sections for TA276

  9. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.

    Technology appraisal guidance
    Published
    26 February 2025

    Sections for TA1043

  10. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

    HealthTech guidance
    Published
    19 June 2025
    View recommendations

    Sections for HTG751

  11. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

    HealthTech guidance
    Published
    24 May 2023
    View recommendations

    Sections for HTG677

  12. Anaemia management in people with chronic kidney disease (CG114)

    This guideline has been updated and replaced by NICE guideline NG8.

    Withdrawn guideline

  13. Chronic kidney disease in adults: assessment and management (CG182)

    This guidance has been updated and replaced by NICE guideline NG203.

    Withdrawn guideline

  14. Anaemia management in people with chronic kidney disease (CG39)

    This guideline has been updated and replaced by NICE guideline CG114.

    Withdrawn guideline

  15. Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA587